# GOLDILOKs: Genomic- and Ontogeny-Linked Dose Individualization and cLinical Optimization for Kids

> **NIH NIH P50** · CHILDREN'S MERCY HOSP (KANSAS CITY, MO) · 2020 · $483,485

## Abstract

RFA-HD-16-014 “Specialized Centers in Research in Pediatric Developmental Pharmacology” (RPDP),
identifies two major barriers that must be overcome to address existing knowledge deficits and bring
precision therapeutics to children of all ages: 1) the limited number of experts trained in pediatric
pharmacology, and 2) the lack of essential information related to developmental changes in drug
disposition and response, and analytical tools and techniques calibrated for pediatric use with which to
acquire this information. The Administrative Core of the “GOLDILOKs: Genomic- and Ontogeny-Linked
Dose Individualization and cLinical Optimization for Kids” Specialized Center in Research in Pediatric
Developmental Pharmacology (RPDP) has been designed to bring together internationally recognized
expertise in pharmacometabolomics, quantitative systems pharmacology, and statistical genomics
together with a large, multi-disciplinary pediatric clinical pharmacology program to address these current
deficits by 1) building multidisciplinary teams to investigate clinically relevant problems related to
variability in drug response across all pediatric subspecialties, 2) creating a culture that enables
integration of cross-disciplinary research focused on important problems in clinical care settings, and 3)
providing didactic and experiential training for pediatric subspecialists interested in developmental
pharmacology-focused research program. The leadership team of the Administrative Core has
considerable experience, and complementary clinical and research expertise in pediatric clinical
pharmacology, pharmacogenetics, clinical study design, pharmacokinetics, developmental & behavioral
pediatrics, and genomic medicine. They will be responsible for oversight of the projects, programs and
activities at Children's Mercy Hospital, including the education and training program built around the
institutional T32 Pediatric Clinical Pharmacology Training Program's didactic and experiential training
opportunities, and will contribute their expertise to the Specialized Centers' Steering Committee. They
will be guided by a local Executive Committee with representation from the Chair of Pediatrics, Chief
Scientific Officer/Executive Director of the Children's Research Institute, as well as an External Advisory
Committee with expertise in clinical investigations integrating pharmacogenomics and metabolomics,
pediatric pharmacometrics, neuropsychiatric pharmacogenetics and pediatric clinical pharmacology.

## Key facts

- **NIH application ID:** 9976567
- **Project number:** 5P50HD090258-05
- **Recipient organization:** CHILDREN'S MERCY HOSP (KANSAS CITY, MO)
- **Principal Investigator:** JAMES STEVEN LEEDER
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $483,485
- **Award type:** 5
- **Project period:** — → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9976567

## Citation

> US National Institutes of Health, RePORTER application 9976567, GOLDILOKs: Genomic- and Ontogeny-Linked Dose Individualization and cLinical Optimization for Kids (5P50HD090258-05). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9976567. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*